Payment overview · 2025
General Payments
$26,877.29
73 reported records · 14 companies
Healthcare provider profile · identity verified
Lauren Gluck, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BRONX, NY · NPI 1033524780
Verified facts
What the public records show
CMS Open Payments records show Lauren Gluck, MD received $26,877.29 in general payments during 2025 across 73 reported records.
Amgen Inc. accounted for 50.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ocrevus, Ponvory.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Tecfidera by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ocrevus as an associated drug or biological on 3064 records involving 1133 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ocrevus by this doctor in 2024.
Genentech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ocrevus as an associated drug or biological on 450 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ocrevus by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mayzent by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PONVORY as an associated drug or biological on 6985 records involving 2313 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ponvory by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $13,474.56 | 50.1% | 24 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $6,183.12 | 23.0% | 11 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $6,113.15 | 22.7% | 9 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $289.32 | 1.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $278.59 | 1.0% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $271.09 | 1.0% | 8 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $74.45 | 0.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $54.40 | 0.2% | 2 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $33.33 | 0.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $25.55 | 0.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.89 | 0.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.37 | 0.1% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $21.28 | 0.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $15.19 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $22,229.63 | 10 |
| Food and Beverage | $2,676.03 | 56 |
| Travel and Lodging | $1,971.63 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $13,474.56 | 24 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $6,113.15 | 9 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $2,400.00 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $271.09 | 8 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $260.61 | 5 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $240.20 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $74.45 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $49.12 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.92 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech, Inc. | $33.33 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ocrevus ocrevus |
2025 | Ocrevus | 2024 | 14 | exact normalized | Medicare Part D |
| PONVORY ponvory |
2025 | Ponvory | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Ocrevus open payments reported associated product |
CMS Open Payments — General Payments 3064 supporting records · 1133 recipient NPIs · example record 1211488404 |
Ocrevus · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| Genentech, Inc. Exact reporting entity; no affiliate inference |
2025 | Ocrevus open payments reported associated product |
CMS Open Payments — General Payments 450 supporting records · 299 recipient NPIs · example record 1211488540 |
Ocrevus · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | PONVORY open payments reported associated product |
CMS Open Payments — General Payments 6985 supporting records · 2313 recipient NPIs · example record 1232940557 |
Ponvory · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 184 | 50 |
| Baclofen | Baclofen | 105 | 35 |
| Pregabalin | Pregabalin | 77 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 15 |
| Dimethyl Fumarate | Dimethyl Fumarate | 57 | suppressed |
| Topiramate | Topiramate | 56 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 15 |
| Dalfampridine Er | Dalfampridine | 31 | suppressed |
| Kesimpta Pen | Ofatumumab | 31 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | 11 |
| Mayzent | Siponimod | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Tecfidera | Dimethyl Fumarate | 26 | suppressed |
| Modafinil | Modafinil | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Aubagio | Teriflunomide | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Teriflunomide | Teriflunomide | 18 | suppressed |
| Entecavir | Entecavir | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Ocrevus | Ocrelizumab | 14 | 12 |
| Prednisone | Prednisone | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Gilenya | Fingolimod Hcl | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Ponvory | Ponesimod | 13 | suppressed |
| Zeposia | Ozanimod Hydrochloride | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $26,877.29 · 73 records | Amgen Inc. | BOTOX, BRIUMVI, Bafiertam, KESIMPTA, Mavenclad, Ocrevus, Ocrevus Zunovo, PONVORY, QULIPTA, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, ZEMBRACE SYMTOUCH | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ocrevus play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Biogen, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error